Immunovant (IMVT) Q1 2027 earnings review
All In On IMVT-1402 After Batoclimab Exit
Immunovant's Q1 FY27 marks its first clean quarter as a single-asset company following the April 2026 discontinuation of batoclimab. Net loss widened to $153.2M as R&D expenses surged to $142.6M to support six ongoing IMVT-1402 trials. With $797.8M in cash (burning ~$104M this quarter), management reaffirmed its runway extends through the potential Graves' disease (GD) launch. The narrative now shifts entirely to execution, with near-term catalysts in CLE and D2T RA expected in the second half of CY2026 defining the next phase of the company.
🐂 Bull Case
Discontinuing batoclimab removes a pipeline distraction and redirects all resources to IMVT-1402, a potential best-in-class anti-FcRn inhibitor.
$798M in cash provides a comfortable multi-year bridge to the projected GD launch, mitigating near-term dilution risk.
🐻 Bear Case
With batoclimab dead after the Phase 3 TED failure, Immunovant is entirely dependent on IMVT-1402's clinical and commercial success.
R&D expenses remained flat sequentially at $142.6M despite the absence of last quarter's $39M batoclimab discontinuation charge, indicating core trial costs are surging.
⚖️ Verdict: ⚪
Neutral. The strategic focus is much clearer, and the balance sheet is formidable. However, the rapidly accelerating core R&D burn and the all-or-nothing reliance on IMVT-1402 raise the stakes considerably heading into the H2 2026 data readouts.
Key Themes
IMVT-1402 Broad Clinical Advancement
Accelerating. IMVT-1402, Immunovant's next-generation anti-FcRn technology, is designed to deliver deep IgG suppression via a simple subcutaneous injection. Following the discontinuation of batoclimab, the company is pushing IMVT-1402 across six parallel indications (GD, MG, CIDP, D2T RA, SjD, CLE). This aggressive trial design allows the company to target a massive total addressable market simultaneously, representing a major evolution in how pipeline-in-a-product assets are developed.
H2 2026 Clinical Catalysts
Accelerating. The second half of 2026 is critical, with topline data from the CLE proof-of-concept trial and further updates on the D2T RA program. The open-label D2T RA data previously showed a 72.7% ACR20 response rate, and translating this into the next update could significantly de-risk the asset.
G&A Expense Optimization
Decelerating. G&A expenses fell 32% YoY from $26.0M to $17.7M, marking a clear deceleration. The company successfully reduced personnel, market research, and IT costs, maximizing the capital available for core clinical development.
Single Asset Binary Risk
Stable. Following the April 2026 discontinuation of batoclimab due to Phase 3 failures in TED, Immunovant is entirely dependent on IMVT-1402. While this sharpens focus, it leaves the company with zero pipeline diversification if IMVT-1402 encounters safety or efficacy hurdles.
Underlying R&D Costs Accelerating
Accelerating. Management noted in the press release that the YoY R&D increase was 'partially offset by lower overall costs as we wind-down our batoclimab clinical trials.' However, total R&D expenses stayed flat sequentially at $142.6M versus $142.3M in Q4. Crucially, Q4 included a $39M one-time contractual charge for the batoclimab discontinuation. The fact that Q1 R&D matched Q4 despite the absence of this $39M charge reveals that underlying clinical costs for IMVT-1402 are accelerating rapidly and completely offsetting the batoclimab savings.
Intensifying FcRn Competitive Landscape
Stable. The broader macroeconomic environment for autoimmune therapies is becoming increasingly crowded. Analysts have previously flagged the risk of fast-followers, such as argenx, aggressively entering the Graves' disease space. While Immunovant's management asserts their deep IgG suppression provides a significant moat, the reality of deep-pocketed competitors means any delay or slight efficacy miss in the upcoming 2027 GD trials could severely punish the stock.
Other KPIs
Accelerating. Non-GAAP net loss widened from $102.1M a year ago to $139.4M. This measure excludes $13.8M in stock-based compensation. The widening loss directly reflects the aggressive clinical expansion and contract manufacturing scale-up for IMVT-1402.
Stable. Shares outstanding only ticked up slightly from 203.9 million at the end of FY26 (March 31, 2026), reflecting minimal dilution in the current quarter as the company relies on its massive cash reserve rather than equity financing.
Guidance
Stable timeline. The proof-of-concept trial is fully enrolled, and this readout will be the first major near-term test of IMVT-1402's efficacy in a new indication following the batoclimab discontinuation.
Stable timeline. After demonstrating a 72.7% ACR20 response rate in the open-label Period 1, the market is eager for the next set of data. Management has historically been cautious about setting high expectations due to the heavily pre-treated nature of this population.
Stable runway. The $797.8M cash balance is projected to fund operations to the potential commercial launch of IMVT-1402 in Graves' disease. With a current quarterly burn of ~$104M, the company has roughly 7-8 quarters of runway, comfortably aligning with the CY2027 Phase 3 readout timelines.
Key Questions
D2T RA Expectations
Given the heavily pre-treated nature of the D2T RA population, what specific efficacy benchmarks (e.g., ACR50/ACR70) will management consider a definitive 'win' in the upcoming H2 2026 update?
Underlying R&D Run Rate
With the $39M batoclimab shutdown charge behind you, Q1 R&D expenses still held at $142.6M. Does this represent the new normalized quarterly run rate as the six IMVT-1402 trials progress, or should we expect further escalation?
Graves' Disease Timeline
Your cash runway guidance is pegged to the 'potential launch' of IMVT-1402 in Graves' disease. What specific year and quarter does your internal base-case model assume for this launch event?